Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action

A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.

Research analyst adding reagent to drug to keep tracking chemical reaction - Image

An appeals court finding that a diagnostic method was directed to a natural law, and thus not patent eligible, has prompted renewed calls for Congressional action to prevent such rulings.

In its Feb. 6 decision in Athena Diagnostics Inc. v. Mayo Collaborative Services LLC, the US Court of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet